Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin for Female Androgenetic Alopecia
NCT07012486Phase 1Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2025
- Primary completion
- May 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dihydroartemisinin in androgenetic alopecia (AGA) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Improvement in terminal hair follicles in the vertex area at 180 days. Started Jun 2025; status: recruiting.
02
Drugs
dihydroartemisinin
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT07012486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012486.